Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Xencor Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Pharmaceutical Preparations
No intraday reading yet this session.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In 2019, we entered into a Patent License Agreement (the "Vir Bio Agreement") with Vir Bio, granting a non-exclusive license to our Xtend technology for up to two targets.”
FILING10-K0001326732-26-000015cik 0001326732
“Under the terms of the Alexion Agreement, we granted to Alexion an exclusive research license, with limited sublicensing rights, to make and use our Xtend technology to evaluate and advance compounds.”
FILING10-K0001326732-26-000015cik 0001326732
“In September 2015, we entered into a Research and License Agreement (the "Amgen Agreement") with Amgen to develop and commercialize bispecific antibody product candidates using our proprietary XmAb® bispecific Fc technology.”
FILING10-K0001326732-26-000015cik 0001326732
“In February 2024, Incyte assumed all of MorphoSys AG's right, title and interest under the MorphoSys Agreement.”
FILING10-K0001326732-26-000015cik 0001326732
“On December 22, 2023, we entered into a Technology License Agreement with Mabgeek.”
FILING10-K0001326732-26-000015cik 0001326732
“In June 2010, we entered into a Collaboration and License Agreement with MorphoSys AG, which was subsequently amended in 2012, 2020 and 2024 (as amended, the "MorphoSys Agreement").”
FILING10-K0001326732-26-000015cik 0001326732
“In June 2016, we entered into a Collaboration and License Agreement (the "Novartis Agreement") with Novartis to develop and commercialize bispecific and other Fc-engineered antibody product candidates using our proprietary XmAb® technologies.”
FILING10-K0001326732-26-000015cik 0001326732
“In February 2025, we entered into a master services agreement with Alimentiv Inc. for contract research organizations ("CROs") services supporting clinical trial management and development (including site selection, study design, site monitoring, management and training, and patient selection).”
FILING10-K0001326732-26-000015cik 0001326732
“In April 2021, we entered into a non-exclusive license agreement with BIO-TECHNE for a recombinant monoclonal antibody reactive with human CLDN6, which is used in our XmAb541 program.”
FILING10-K0001326732-26-000015cik 0001326732
“ICON Clinical Research Limited provides clinical services for our Xencor-sponsored oncology trials.”
FILING10-K0001326732-26-000015cik 0001326732
“In July 2014, we entered into a master services agreement with KBI Biopharma, Inc. for process development, clinical scale-up, analytical method development, formulation development, and related drug substance and drug product services for certain antibody candidates, including XmAb541 and plamotamab.”
FILING10-K0001326732-26-000015cik 0001326732
“In August 2023, we entered into a master services agreement with OncoBay Clinical, Inc., now known as Kapadi, for CROs services supporting clinical trial management and development (including site selection, study design, site monitoring, management and training, and patient selection).”
FILING10-K0001326732-26-000015cik 0001326732
“PAREXEL conducts clinical studies for our plamotamab program.”
FILING10-K0001326732-26-000015cik 0001326732
“PPD Development, L.P. conducts clinical studies for our vudalimab program.”
FILING10-K0001326732-26-000015cik 0001326732
“In December 2015, we entered into a master services agreement with Selexis SA for the manufacture of proprietary cell lines.”
FILING10-K0001326732-26-000015cik 0001326732
“Vetter Pharma International GmbH currently manufactures drug products for our XmAb819 and XmAb541 programs.”
FILING10-K0001326732-26-000015cik 0001326732
“WuXi currently manufactures drug substance and drug product for our XmAb808, XmAb657, XmAb942 and XmAb412 programs.”
FILING10-K0001326732-26-000015cik 0001326732
“In November 2020, we entered into an agreement with J&J (the J&J Agreement) to develop XmAb bispecific antibodies against CD28 and a prostate tumor target, for the potential treatment of patients with prostate cancer, and from the collaboration, J&J selected JNJ-9401, which is currently in a Phase 1 clinical study.”
FILING10-K0001326732-26-000015cik 0001326732
“On February 27, 2023, we entered into a sales agreement (the Sales Agreement) with SVB Securities LLC (the Agent) pursuant to which we may offer and sell, from time to time, through the Agent (the ATM Offering), shares of our common stock having an aggregate offering price of up to $200 million (the ATM Shares).”
FILING10-K0001326732-26-000015cik 0001326732
“In September 2020, we entered into a license agreement (the "2020 Xencor Agreement") with Xencor, to obtain (i) an exclusive, royalty-bearing, sublicensable worldwide license under certain patent rights controlled by Xencor and (ii) a non-exclusive payment bearing license under certain know-how controlled by Xencor to research, develop, manufacture, market and sell three antibody product candidates (the "2020 Licensed Assets"), including ZB002 and ZB004.”
FILING10-K0001104659-26-027964cik 0001953926disclosed by ZBIO
“Our molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.”
FILING10-K0002019410-26-000016cik 0002019410disclosed by CAI
“Astellas : ASP2138 is a bispecific Claudin 18.2 x CD3 bispecific antibody that Astellas is advancing for the treatment of patients with gastric, gastroesophageal junction or pancreatic cancers.”
FILING10-K0001326732-26-000015cik 0001326732
Watchlist prices, news filtered to it, and its next report on your desk.
Xencor Inc has 12 disclosed suppliers and 10 disclosed customers. Each one is named in an SEC filing, either Xencor Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
XNCR (Xencor Inc) has 12 disclosed suppliers and 10 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: VIR −4.13%, in healthcare.